Menu Search
Equities

Mochida Pharmaceutical Co Ltd

MFY:FRA

Mochida Pharmaceutical Co Ltd

Actions
  • Price (EUR)18.30
  • Today's Change0.00 / 0.00%
  • Shares traded-1.00
  • 1 Year change-19.74%
  • Beta--
Data delayed at least 15 minutes, as of Apr 26 2024 07:19 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Mochida Pharmaceutical Co Ltd is a Japan-based company principally engaged in the production and sale of drugs. The Pharmaceutical-related segment is engaged in the manufacture, purchase and sale of pharmaceutical products. The Company also conducts brokerage and management of real estate properties, the maintenance and management of buildings, the agency of personal affairs, accounting and purchasing businesses. The Healthcare segment is involved in the manufacture, purchase and sale of quasi drugs and cosmetic products.

  • Revenue in JPY (TTM)100.09bn
  • Net income in JPY3.01bn
  • Incorporated1945
  • Employees1.53k
  • Location
    Mochida Pharmaceutical Co Ltd1-7, YotsuyaSHINJUKU-KU 160-8515JapanJPN
  • Phone+81 333587211
  • Fax+81 333587887
  • Websitehttps://www.mochida.co.jp/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.